Form 4: Vaxcyte Director Heath Lukatch Acquires Shares

Vaxcyte, Inc. Director Heath Lukatch reported the acquisition of 2,265 shares of common stock and the grant of stock options for 11,389 shares.

Summary

• Director Heath Lukatch acquired 2,265 shares of Vaxcyte, Inc. common stock on June 15, 2026.
• The acquisition of these shares had a reported price of $0.
• Additionally, Mr. Lukatch was granted stock options to purchase 11,389 shares of common stock at an exercise price of $49.56 per share.
• These stock options are set to vest monthly and will fully vest on the earlier of June 15, 2027, or the day prior to the next annual meeting of stockholders, subject to continuous service.
• Following these transactions, Mr. Lukatch beneficially owns 19,481 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine insider transactions (share acquisition and option grant) rather than significant new strategic information or financial performance indicators.

Positives

• Director Heath Lukatch has acquired additional shares in the company, indicating confidence.
• The grant of stock options suggests a long-term incentive aligned with the company's performance.
• The acquisition of 2,265 shares at $0 cost is a direct increase in beneficial ownership for the director.

Negatives

• The exercise price of the stock options ($49.56) is significantly higher than the current market price implied by the $0 acquisition cost of the underlying shares, suggesting a substantial increase in stock price is needed for these options to be in-the-money.

Risks

• The vesting of RSUs and stock options is contingent upon the Reporting Person's continuous service through the vesting date, meaning departure from the company before these dates would result in forfeiture.
• The stock options have an expiration date of June 15, 2036, but their value is dependent on the future stock price performance of Vaxcyte, Inc.

Future Outlook

The vesting of restricted stock units and stock options is tied to specific future dates (June 15, 2027, or the day prior to the next annual meeting) and contingent on the reporting person's continued employment with Vaxcyte, Inc.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The acquisition of shares and grant of options by a director are common practices to align management's interests with shareholders, particularly in biotechnology companies where long-term development and market success are crucial.

Stakeholder Impact

• Shareholders: The acquisition of shares by a director may be viewed positively as a sign of confidence, but the high exercise price of options indicates a need for significant future stock price appreciation to benefit the director.
• Employees: The vesting schedules for RSUs and options are tied to continuous service, incentivizing employee retention.
• Management: The transactions directly impact the beneficial ownership and potential future wealth of Director Heath Lukatch.

Next Steps

• Vesting of 2,265 RSUs on or before June 15, 2027.
• Vesting of 11,389 stock options on or before June 15, 2027.
• Potential exercise of stock options after vesting, subject to market conditions and the $49.56 exercise price.

Key Dates

Keywords

Vaxcyte, PCVX, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Beneficial Ownership, Director, Securities Exchange Act